Antiphospholipid syndrome (APS) is classified into primaryand secondary. Systemic lupus erythematosus (SLE) is the mostcommon cause of secondary APS. The prevalence of APLAs,either LA or ACLAs, in patients with SLE is high (Roubey, 2004).Objective: This study was designed to determine the frequency ofanti-phospholipid antibodies, (aCL IgG, aCL IgM & LA) in pediatricSLE patients, and their correlation with the associated clinicalmanifestations in Egyptian children.Patients and methods: This study included 50 lupus patientsfollowed in the pediatric rheumatology clinic, having at least 4 ofthe American College of Rheumatology revised criteria for theclassification of systemic lupus erythematosus. Antiphospholipidantibodies were tested in these patients.Results: aCL IgG, aCL IgM and LA were positive in 24%, 34% and28% of the patients respectively. 22% of the patients werediagnosed as SAPS. Positive correlation was found between thepresence of APLA and evidence of thrombosis, vasculiticmanifestations, neuropsychiatric manifestations, hemolytic anemiaand gastrointestinal manifestations.Conclusion: From our study we can conclude that the presence ofAPLA is common in pediatric SLE patients, so screening for APLAin SLE patients is recommended, and also repeated testing isrecommended, which reveals the value of prophylactic treatmentfor APS in asymptomatic SLE patients with a positive APLA.